

Friday, December 3, 2021

Session VI: Clinical Electrophysiology

Chairs: *Christine M. Albert, MD, MPH, FACC, Sumeet Chugh, MD, FACC, Eli Gang, MD, FACC, Jeffrey Goodman, MD, FACC*

Device-Detected Atrial Fibrillation: NOAC or Not? (5 min Q&A)

Roopinder Sandhu, MD MPH

Clinical Pearls for P.O.T.S. (Postural Orthostatic Tachycardia Syndrome) (5 min Q&A)

Peng-Sheng Chen, MD, FACC

Debate: The Future of Primary Prevention ICDs

• Will Only Benefit Patients with EF <35%

Eric C. Stecker, MD, MPH, FACC

• Will Have the Most Impact in Patients with EF >35%

Sumeet Chugh, MD, FACC

• Rebuttal and Discussion

Session VII: Hypertension

Chair: *Florian Rader, MD, MSc, FACC*

Debate: Aldosterone Blockade vs. Thiazide Diuretics: Which is the Superior Antihypertensive?

• Aldo Blockers and New Trials

Florian Rader, MD, MSc, FACC

• Thiazides, But They Are Not All Created Equal!

Natalie Bello, MD, MPH, FACC

Debate: Race and HTN: True Biologic Difference or Just a Surrogate Marker?

• Main Discussion

Joseph Ebinger, MD, MS, FACC

• What Did We Learn from the Barbershop Trials?

C. Adair Blyler, PharmD, CHC

Debate: Out-of-Office Blood Pressure Monitoring for the Management of Hypertension

• Home and Ambulatory BP Monitoring Are Essential Tools

Michael Weber, MD, FACC

• Ambulatory BP Monitoring is an Antiquated and Impractical Tool

Raj Khandwalla, MD, MA, FACC

Panel Discussion:

Natalie Bello, MD, MPH, FACC, C. Adair Blyler, PharmD, CHC, Joseph Ebinger, MD, MS, FACC, Raj Khandwalla, MD, FACC, Florian Rader, MD, MSc, FACC, Michael Weber, MD, FACC

Session VIII:

Update on Practice-Changing CV Trials of 2021

Chair:

Sanjay Kaul, MD, MPH, FACC

Discussants:

George Bakris, MD, MA, Raj Makkar, MD, FACC,

Steven E. Nissen, MD, MACC, Milton Packer, MD, FACC,

Peter Toth, MD, PhD, FACC

N-3 PUFA: Do They Improve CV Outcomes? Reconciling Discordant Cardiorenal Metabolic Outcome Trials

SGLT2 Inhibitors: Are They the Modern-Day Statins? Insights from Recent Cardiorenal Metabolic Outcome Trials

TAVI for Low-Risk Severe Aortic Stenosis: Do We Have Sufficient Data to Inform the Guidelines?

Role of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Mitigating Cardiorenal Risk in T2 Diabetes